Expected Impact of Biosimilars on the Pharmaceutical Companies.
Iranian journal of medical sciences, 2021 In the last three decades, biological products have gradually developed to be an essential basis in the pharmaceutical industry. Advancements in this field have encouraged the frontiers of science to bring life-saving treatments to patients suffering from incurable diseases, such as cancers and has also assisted clinicians in managing chronic diseases ...
Shiva Golshani, Mohammad Ali Faramarzi
openalex +5 more sources
Generics, Biosimilars, and the Ethics of Pricing Pharmaceuticals [PDF]
Journal of Veterinary Science & Medicine, 2016 Recent price hikes by pharmaceutical companies underscore the importance of competition in an industry that often sets prices according to what the market will bear. A steady pipeline of generics and biosimilars is the surest check to the rising prices of drugs and biologics.
Mark A. Brown
openalex +2 more sources
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure [PDF]
Frontiers in Pharmacology, 2021 Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies.
Sabine Vogler +4 more
openalex +5 more sources
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? [PDF]
The European Journal of Health Economics, 2013 Biological medicines contain a biological substance that is produced by or derived from a living organism. The active substances of biologicals are usually larger and more complex than those of chemically derived medicines (non-biological medicine). Biologicals are used for the treatment of chronic and life-threatening diseases such as cancer, multiple
María-Isabel Farfan-Portet +4 more
openalex +4 more sources
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS [PDF]
Current Pharmaceutical Biotechnology, 2016 Therapeutic monoclonal antibodies (mAbs) have made a tremendous impact in treating patients with various diseases. MAbs are designed to specifically target a cell and illicit a response from the immune system to destroy the cell. As originator mAb drug patents are coming to an end, generic pharmaceutical companies are poised to replicate and produce so-
Kerry M. Wooding +2 more
openalex +4 more sources
Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry [PDF]
DARU Journal of Pharmaceutical Sciences, 2012 In 1980s, medicines produced through recombinant DNA technology created a novel opportunity for management of several debilitating and life threatening diseases. However, these medicines are very expensive and therefore not affordable for many patients especially those living in low resourced countries.
Abdol Majid Cheraghali
openalex +3 more sources
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review [PDF]
Endocrinology, Diabetes & MetabolismBackground The option to switch patients to more cost‐effective biosimilar insulins has been available since 2014, and the market share for these medicines has been slowly increasing since then. This scoping review aimed to identify the current knowledge
Ben Hindley +4 more
doaj +2 more sources
Purification Process of a Recombinant Human Follicle Stimulating Hormone Biosimilar (Primapur®) to Yield a Pharmaceutical Product with High Batch-to-Batch Consistency [PDF]
Pharmaceutics, 2022 Recombinant human follicle stimulating hormone (r-hFSH) is widely used for infertility treatment and is subject to the development of biosimilars. There are different purification strategies that can yield r-hFSH of pharmaceutical quality from Chinese hamster ovary cell culture broth.
Maria V. Sinegubova +6 more
openalex +5 more sources
European Journal of Pharmaceutical Sciences, 2022 Pharmaceutical development of biosimilars is primarily focused on meeting the regulatory requirements for analytical comparability of the product's critical quality attributes (CQAs), concerning safety and efficacy, to those of the originator drug of interest.
Morteza Jaffar-Aghaei +9 more
openalex +3 more sources
A PHARMACEUTICAL GUIDE TO ADALIMUMAB BIOSIMILARS [PDF]
FARMACIA, 2022 Ammar Almaaytah
openalex +2 more sources